Rifaximin treatment in patients with severe alcoholic hepatitis: A multicenter, randomized controlled, open-label, pilot trial

Rifaximin treatment in patients with severe alcoholic hepatitis: A multicenter, randomized controlled, open-label, pilot trial

Introduction and Objectives: The short-term mortality of severe alcoholic-associated hepatitis (SAH) is high, but there are no effective treatments to improve short-term mortality other than corticosteroids. This study investigated the effects of adding rifaximin to standard treatment in patients wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Do Seon Song, Jin Mo Yang, Young Kul Jung, Hyung Joon Yim, Hee Yeon Kim, Chang Wook Kim, Soon Sun Kim, Jae Youn Cheong, Hae Lim Lee, Sung Won Lee, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Annals of Hepatology
Subjects:
Rifaximin
Gut microbiome
Endotoxin
SAH, severe alcohol-associated hepatitis
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268124005325
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1665268124005325

Similar Items